Please send all media-related inquiries and interview requests to firstname.lastname@example.org. An LLS representative will respond as soon as possible.
Rye Brook, N.Y., January 27, 2023 – The U.S. Food and Drug Administration today approved pirtobrutinib (Jaypirca™), the first non-covalent, reversable BTK inhibitor for the treatment of adults with mantle cell lymphoma that has worsened or returned despite earlier treatment.
Rye Brook, NY, January 11, 2023 -- The Leukemia & Lymphoma Society today joins with the blood cancer community in mourning the death of C. David Allis, PhD, a founding member of one of the largest LLS grant programs, Specialized Center of Research (SCOR). We extend our condolences to his family, friends, and colleagues.Read More
Insured Cancer Patients Continue to Face Barriers To Medically Necessary Treatment, New Report WarnsPosted On: January 9, 2023
WASHINGTON, D.C., January 9, 2023 – A new report from a national cancer nonprofit warns that delays and red tape jeopardize patients’ access to lifesaving cancer care — even when they have high-quality health insurance.Read More
The Leukemia & Lymphoma Society Honors Six Outstanding Blood Cancer Scientists with 2022 Achievement AwardsPosted On: December 23, 2022 Read More
The Leukemia & Lymphoma Society’s Presence at ASH Showcases Progress to Advance Cures and Care for Blood Cancer PatientsPosted On: November 28, 2022
RYE BROOK, N.Y., November 28, 2022 – At the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13), The Leukemia & Lymphoma Society (LLS) will be presenting new research, leading sessions on the latest innovations in blood cancer treatment and equitable access to care, and proudly supporting hundreds of LLS-funded researchers who will share their findings. Read More
Rye Brook, N.Y. - The Leukemia & Lymphoma Society is proud to announce that its strong financial health and ongoing accountability and transparency have earned LLS a Four-Star Rating from Charity Navigator. Read More